EMA is advising marketing authorisation holders to submit individual type IA and type IAIN variations and super-groupings for 2025 no later than 21st November, 2025. This will enable EMA to ...
New guidelines aim to streamline lifecycle management and adapt to scientific and technological advancements in drug development. Variations are classified into Type IA, Type IB, and Type II based on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback